Research of the Active Components and Potential Mechanisms of Qingfei Gujin Decoction in the Treatment of Osteosarcoma Based on Network Pharmacology and Molecular Docking Technology

Table 4

Common treatment of osteosarcoma.

Low-grade osteosarcoma	Surgical therapy
High-grade osteosarcoma	Localized disease	Neoadjuvant chemotherapy/chemotherapy	AP (DDP-ADM) [23]
			MAP (HD-MTX, DDP, ADM) [24]
			IAP (IFO, DDP, ADM) [25]
			M-EI (MTX-etoposide-IFO) [26]
		Recurrent/refractory/metastatic	Pirarubicin-DDP [27]
			Paclitaxel-doxorubicin [28]
			Cyclophosphamide-VP-16 [29]
			Gemcitabine-docetaxel [30]
			Pemetrexed [31]
	Lung metastasis	Removable metastases	Neoadjuvant chemotherapy-extensive resection-excision of metastases
		Unresectable metastases	Chemotherapy and (or) radiotherapy
		Immunotherapy	IL-2 [32]
			Chimeric antigen receptor T cells (CAR-T) [33]
			Pembrolizumab [34]
			Camrelizumab [35]
			Durvalumab-tremelimumab [36]
		Molecular targeted therapy	Sorafenib [37]
			Sorafenib-everolimus [38]
			Regorafenib [39]
			Cabozantinib [40]
			Anlotinib [41]
			Apatinib [42]
		Antiangiogenic drugs	Endostar [43]
			Bevacizumab [44]